What “success rate” usually means for Vivitrol in opioid recovery
People typically ask about Vivitrol’s success rate in terms of one (or more) of these outcomes: staying in treatment (retention), reducing opioid use, avoiding relapse after detox, or achieving abstinence. The best available evidence usually reports these outcomes in clinical trials, but the exact “success rate” number depends on the definition used and the study population (for example, people who are fully detoxified vs. those with more recent use).
What the evidence says about outcomes with Vivitrol (naltrexone) after detox
Vivitrol is extended-release naltrexone. It blocks opioid effects, which can reduce the risk of relapse for people who are opioid-free at the time they start treatment. In studies of opioid relapse prevention, patients assigned to extended-release naltrexone generally did better than placebo on relapse-related endpoints, particularly when adherence to treatment and opioid-free start conditions were met.
At the same time, “success rate” is not one single fixed percentage across studies: real-world effectiveness also depends heavily on whether a person can start treatment safely after detox (naltrexone requires that people are opioid-free to avoid precipitated withdrawal) and whether they remain engaged with follow-up care.
Why there isn’t one universal success percentage
A single success-rate figure is hard to justify because results vary with:
- How relapse is defined (any opioid use vs. opioid-free weeks/months).
- Whether outcomes are measured as “relapse to opioid use,” “incarceration,” “treatment discontinuation,” or other endpoints.
- Baseline risk (people differ in severity and history).
- Treatment pathway quality (counseling, case management, and follow-up often move outcomes more than medication alone).
So, if you’re searching for a precise “X% success rate,” it will depend on which trial and which endpoint you mean.
How clinicians and patients often judge whether it’s working
In practice, people often look for:
- Fewer opioid-positive results or self-reported opioid use
- Longer time without relapse
- Staying on the injection schedule
- Fewer opioid overdoses (naltrexone blocks opioid effects, but it does not prevent overdose from non-opioids or from attempts to override the blockade)
If you want, I can give a precise number—what definition do you mean?
If you tell me which outcome you mean by “success rate” (for example, “relapse prevention,” “opioid-free at 6 months,” or “treatment retention”), I can narrow to the matching trial results.
Also, if you want the most “real-world” view vs. “clinical trial” view, say so and I’ll tailor the answer.
Sources
No sources were provided with your question, and I don’t have enough specific details here to cite a particular success-rate percentage from a study or registry.